No Data
No Data
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5
B.Riley Financial analyst Mayank Mamtani maintains $Vaxart(VXRT.US)$ with a buy rating, and maintains the target price at $2.5.According to TipRanks data, the analyst has a success rate of 27.3% and
Buy Rating Affirmed for Vaxart Amidst Promising Norovirus Vaccine Developments and Market Opportunity
While Institutions Invested in Vaxart, Inc. (NASDAQ:VXRT) Benefited From Last Week's 23% Gain, Retail Investors Stood to Gain the Most
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones index closed higher by around 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and trader
Vaxart(VXRT.US) Director Buys US$13,578 in Common Stock
$Vaxart(VXRT.US)$ Director Watson W. Mark purchased 20,000 shares of common stock on Jun 18, 2024 at an average price of $0.6789 for a total value of $13,578.Source: Announcement What is statement of
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersGeovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. Nexalin Technology (NASDAQ:NXL) shares incre
No Data